New strategies to improve clinical outcomes for diabetic kidney disease
Abstract Background Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with type 2 diabetes. With the incidence of type 2 diabetes continuing to increase, early detection and management of DKD is of...
Main Authors: | Thomas Forst, Chantal Mathieu, Francesco Giorgino, David C. Wheeler, Nikolaos Papanas, Roland E. Schmieder, Atef Halabi, Oliver Schnell, Marina Streckbein, Katherine R. Tuttle |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12916-022-02539-2 |
Similar Items
-
Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
by: Erin D. Michos, et al.
Published: (2023-06-01) -
Role of Zinc in Diabetic Kidney Disease
by: Guido Gembillo, et al.
Published: (2022-03-01) -
Best Practices in the Use of Sodium–Glucose Cotransporter 2 Inhibitors in Diabetes and Chronic Kidney Disease for Primary Care
by: Jay H. Shubrook, et al.
Published: (2023-10-01) -
Antidiabetic and Other Therapies Used in Subjects with Diabetes and Chronic Kidney Disease in a Hospital-Based Clinic Population in Greece
by: Ilias N. Migdalis, et al.
Published: (2021-05-01) -
Hypertriglyceridemia and Other Risk Factors of Chronic Kidney Disease in Type 2 Diabetes: A Hospital-Based Clinic Population in Greece
by: Ilias N. Migdalis, et al.
Published: (2022-06-01)